About Insulet (NASDAQ:PODD)
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of drugs over a specified interval of time, at an administered volume. The company sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors. Insulet Corporation was founded in 2000 and is headquartered in Billerica, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000
Debt
Debt-to-Equity Ratio3.57%
Current Ratio6.24%
Quick Ratio5.85%
Price-To-Earnings
Trailing P/E Ratio-186.48
Forward P/E Ratio-298.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$463.77 million
Price / Sales10.94
Cash FlowN/A
Price / CashN/A
Book Value$2.72 per share
Price / Book31.77
Profitability
EPS (Most Recent Fiscal Year)($0.46)
Net Income$-26,830,000.00
Net Margins-5.79%
Return on Equity-29.73%
Return on Assets-4.83%
Miscellaneous
Employees857
Outstanding Shares58,690,000
Insulet (NASDAQ:PODD) Frequently Asked Questions
What is Insulet's stock symbol?
Insulet trades on the NASDAQ under the ticker symbol "PODD."
How were Insulet's earnings last quarter?
Insulet Co. (NASDAQ:PODD) issued its earnings results on Wednesday, February, 21st. The medical instruments supplier reported ($0.12) EPS for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.04. The medical instruments supplier earned $130.50 million during the quarter, compared to analysts' expectations of $125.16 million. Insulet had a negative net margin of 5.79% and a negative return on equity of 29.73%. The business's revenue was up 26.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.16) EPS. View Insulet's Earnings History.
When is Insulet's next earnings date?
What price target have analysts set for PODD?
20 Wall Street analysts have issued 1-year target prices for Insulet's shares. Their predictions range from $44.00 to $105.00. On average, they anticipate Insulet's share price to reach $76.7778 in the next year. View Analyst Ratings for Insulet.
What are Wall Street analysts saying about Insulet stock?
Here are some recent quotes from research analysts about Insulet stock:
- 1. According to Zacks Investment Research, "INSULET CORPORATION is an innovative medical device company dedicated to improving the lives of people with diabetes. The Company's OmniPod Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use components with no tubing and fully-automated cannula insertion. Through the OmniPod System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. " (4/26/2018)
- 2. Northland Securities analysts commented, "Epizyme’s loss per share of $0.48 was less than our estimated $0.66. This resulted from higher than estimated revenue, which was $10 million compared to our estimated $0.6 million, and resulted from a milestone payment. Expenses were in line with expectations. Our outlook for 2017-22 remains basically unchanged. We are adjusting our 2017 estimates to reflect the milestone payment in this quarter." (8/4/2017)
Who are some of Insulet's key competitors?
Some companies that are related to Insulet include ResMed (RMD), Abiomed (ABMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), ICU Medical (ICUI), Globus Medical (GMED), Cantel Medical (CMD), Penumbra (PEN), Haemonetics (HAE), NuVasive (NUVA), Nevro (NVRO), Merit Medical Systems (MMSI), NovoCure (NVCR) and Irhythm Technologies (IRTC).
Who are Insulet's key executives?
Insulet's management team includes the folowing people:
- Mr. Patrick J. Sullivan, Chairman & CEO (Age 66)
- Ms. Shacey Petrovic, Pres and Chief Operating Officer (Age 44)
- Mr. Michael L. Levitz, CFO, Sr. VP, Treasurer & Principal Accounting Officer (Age 44)
- Mr. Bradley A. Thomas, Exec. VP of HR & Organizational Devel. (Age 60)
- Mr. Charles Alpuche, Exec. VP of Global Manufacturing and Operations (Age 58)
Has Insulet been receiving favorable news coverage?
News headlines about PODD stock have been trending positive recently, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Insulet earned a media sentiment score of 0.41 on Accern's scale. They also assigned media stories about the medical instruments supplier an impact score of 45.77 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Insulet?
Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insulet's stock price today?
One share of PODD stock can currently be purchased for approximately $86.42.
How big of a company is Insulet?
Insulet has a market capitalization of $4.98 billion and generates $463.77 million in revenue each year. The medical instruments supplier earns $-26,830,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. Insulet employs 857 workers across the globe.
How can I contact Insulet?
Insulet's mailing address is 600 TECHNOLOGY PARK DRIVE SUITE 200, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]
MarketBeat Community Rating for Insulet (PODD)
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Insulet (NASDAQ:PODD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
20 Wall Street analysts have issued ratings and price targets for Insulet in the last 12 months. Their average twelve-month price target is $76.7778, suggesting that the stock has a possible downside of 11.16%. The high price target for PODD is $105.00 and the low price target for PODD is $44.00. There are currently 6 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.70 | 2.67 | 2.71 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
6 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $76.7778 | $73.5625 | $62.1429 | $55.4615 |
| Price Target Upside: | 11.16% downside | 2.98% downside | 9.62% downside | 8.97% downside |
Insulet (NASDAQ:PODD) Consensus Price Target History
Insulet (NASDAQ:PODD) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
Insulet (NASDAQ:PODD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Insulet (NASDAQ PODD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.60%
Insulet (NASDAQ PODD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/16/2018 | Bradley A. Thomas | EVP | Sell | 3,500 | $85.00 | $297,500.00 | |  |
| 3/15/2018 | Charles Alpuche | COO | Sell | 7,090 | $84.65 | $600,168.50 | | |
| 3/14/2018 | Bradley A. Thomas | EVP | Sell | 7,250 | $83.81 | $607,622.50 | | |
| 3/14/2018 | John A. Fallon | Director | Sell | 9,000 | $84.10 | $756,900.00 | | |
| 3/6/2018 | David A. Lemoine | Director | Sell | 641 | $76.81 | $49,235.21 | | |
| 3/6/2018 | Shacey Petrovic | COO | Sell | 1,319 | $76.81 | $101,312.39 | | |
| 11/13/2017 | James C. Mullen | Director | Buy | 2,500 | $67.45 | $168,625.00 | | |
| 9/6/2017 | Charles Alpuche | EVP | Buy | 2,500 | $58.08 | $145,200.00 | | |
| 5/16/2017 | Michael P. Spears | SVP | Buy | 2,500 | $40.59 | $101,475.00 | | |
| 5/11/2017 | Bradley A. Thomas | EVP | Buy | 3,000 | $38.69 | $116,070.00 | | |
| 5/11/2017 | Jessica Hopfield | Director | Buy | 2,580 | $38.68 | $99,794.40 | | |
| 5/1/2017 | David A. Lemoine | Director | Sell | 1,524 | $43.40 | $66,141.60 | | |
| 3/13/2017 | Regina O. Sommer | Director | Sell | 40,000 | $45.00 | $1,800,000.00 | | |
| 3/6/2017 | David A. Lemoine | Director | Sell | 1,282 | $45.15 | $57,882.30 | | |
| 3/2/2017 | Joseph S. Zakrzewski | Director | Sell | 40,000 | $46.86 | $1,874,400.00 | | |
| 12/9/2016 | Charles Alpuche | SVP | Buy | 6,600 | $37.70 | $248,820.00 | | |
| 12/2/2016 | Patrick J. Sullivan | CEO | Buy | 40,000 | $33.89 | $1,355,600.00 | | |
| 12/1/2016 | Bradley A. Thomas | EVP | Buy | 3,100 | $32.45 | $100,595.00 | | |
| 5/25/2016 | Regina O Sommer | Director | Sell | 8,019 | $30.42 | $243,937.98 | 20,330 | |
| 5/18/2016 | Patrick J Sullivan | CEO | Buy | 45,000 | $27.00 | $1,215,000.00 | 202,795 | |
| 5/13/2016 | Bradley A Thomas | EVP | Buy | 2,975 | $26.63 | $79,224.25 | 51,315 | |
| 5/5/2016 | Bradley A Thomas | EVP | Buy | 1,656 | $30.13 | $49,895.28 | 48,340 | |
| 3/10/2016 | Daniel J Levangie | Insider | Sell | 12,299 | $30.89 | $379,916.11 | 25,358 | |
| 3/7/2016 | Daniel J Levangie | Insider | Sell | 7,663 | $31.15 | $238,702.45 | 9,813 | |
| 3/2/2016 | Jessica Hopfield | Director | Buy | 3,230 | $30.91 | $99,839.30 | 8,838 | |
| 6/5/2015 | Patrick J Sullivan | CEO | Buy | 10,000 | $29.39 | $293,900.00 | | |
| 5/28/2015 | Patrick J Sullivan | CEO | Buy | 20,000 | $27.91 | $558,200.00 | | |
| 5/15/2015 | Timothy J Scannell | Director | Buy | 3,500 | $27.05 | $94,675.00 | | |
| 5/5/2015 | Bradley A Thomas | EVP | Buy | 1,000 | $27.26 | $27,260.00 | | |
| 5/5/2015 | Patrick Ryan | COO | Buy | 3,669 | $26.99 | $99,026.31 | | |
| 4/2/2015 | R Anthony Diehl | General Counsel | Sell | 3,372 | $30.96 | $104,397.12 | | |
| 3/9/2015 | Patrick J Sullivan | CEO | Buy | 10,000 | $31.93 | $319,300.00 | | |
| 3/2/2015 | Charles T Liamos | Director | Sell | 4,000 | $32.00 | $128,000.00 | | |
| 2/12/2015 | Charles T Liamos | Director | Sell | 4,000 | $32.00 | $128,000.00 | | |
| 1/2/2015 | Charles T Liamos | Director | Sell | 4,000 | $46.08 | $184,320.00 | | |
| 11/3/2014 | Charles T Liamos | Director | Sell | 4,000 | $42.95 | $171,800.00 | | |
| 10/1/2014 | Charles T Liamos | Director | Sell | 4,000 | $36.58 | $146,320.00 | | |
| 10/1/2014 | R Anthony Diehl | General Counsel | Sell | 1,250 | $36.59 | $45,737.50 | | |
| 9/10/2014 | Charles T Liamos | Director | Sell | 4,000 | $35.17 | $140,680.00 | | |
| 9/2/2014 | Duane Desisto | CEO | Sell | 20,000 | $36.30 | $726,000.00 | | |
| 8/1/2014 | Duane Desisto | CEO | Sell | 20,000 | $34.23 | $684,600.00 | | |
| 7/1/2014 | Duane Desisto | CEO | Sell | 20,000 | $40.52 | $810,400.00 | | |
| 7/1/2014 | R Anthony Diehl | General Counsel | Sell | 1,250 | $39.65 | $49,562.50 | | |
| 6/11/2014 | R Anthony Diehl | General Counsel | Sell | 17,871 | $37.09 | $662,835.39 | | |
| 6/9/2014 | Peter Devlin | Insider | Sell | 12,314 | $37.10 | $456,849.40 | | |
| 4/8/2014 | Peter Devlin | Insider | Sell | 30,000 | $41.25 | $1,237,500.00 | 79,668 | |
| 4/3/2014 | R Anthony Diehl | General Counsel | Sell | 4,617 | $48.67 | $224,709.39 | 53,246 | |
| 3/6/2014 | R Anthony Diehl | General Counsel | Sell | 12,458 | $49.28 | $613,930.24 | 58,246 | |
| 3/6/2014 | Tracey Haas Wielinski | VP | Sell | 8,275 | $49.21 | $407,212.75 | 24,000 | |
| 2/3/2014 | Charles Liamos | Director | Sell | 11,037 | $42.93 | $473,818.41 | 77,316 | |
| 2/3/2014 | Duane Desisto | CEO | Sell | 20,000 | $42.95 | $859,000.00 | 184,293 | |
| 2/3/2014 | Peter Devlin | Insider | Sell | 30,000 | $42.82 | $1,284,600.00 | 63,081 | |
| 1/3/2014 | Charles Liamos | COO | Sell | 86,000 | $36.02 | $3,097,720.00 | 77,316 | |
| 1/2/2014 | Duane Desisto | CEO | Sell | 20,000 | $36.07 | $721,400.00 | 184,293 | |
| 12/3/2013 | Charles Liamos | COO | Sell | 63,808 | $36.26 | $2,313,678.08 | 118,194 | |
| 11/18/2013 | Charles Liamos | COO | Sell | 80,000 | $35.60 | $2,848,000.00 | 118,194 | |
| 9/3/2013 | Duane Desisto | CEO | Sell | 20,000 | $33.38 | $667,600.00 | 182,433 | |
| 8/29/2013 | Sally Crawford | Director | Sell | 9,000 | $33.42 | $300,780.00 | 7,000 | |
| 8/15/2013 | Regina Sommer | Director | Sell | 5,000 | $33.32 | $166,600.00 | 16,500 | |
| 8/1/2013 | Duane Desisto | CEO | Sell | 20,000 | $31.85 | $637,000.00 | | |
| 7/1/2013 | Duane Desisto | CEO | Sell | 20,000 | $31.51 | $630,200.00 | | |
| 7/1/2013 | Peter Devlin | Insider | Sell | 30,000 | $31.48 | $944,400.00 | | |
| 6/14/2013 | Sally Crawford | Director | Sell | 31,000 | $30.47 | $944,570.00 | | |
| 6/10/2013 | R Anthony Diehl | General Counsel | Sell | 38,455 | $30.50 | $1,172,877.50 | | |
| 6/3/2013 | Duane Desisto | CEO | Sell | 20,000 | $29.76 | $595,200.00 | | |
| 12/3/2012 | Brian K Roberts | CFO | Sell | 10,000 | $21.92 | $219,200.00 | | |
| 11/1/2012 | Brian K Roberts | CFO | Sell | 10,000 | $21.49 | $214,900.00 | | |
| 9/4/2012 | Brian K Roberts | CFO | Sell | 10,000 | $20.78 | $207,800.00 | | |
| 9/4/2012 | Duane Desisto | CEO | Sell | 20,000 | $20.97 | $419,400.00 | | |
| 9/4/2012 | Ruthann Depietro | VP | Sell | 1,000 | $20.90 | $20,900.00 | | |
(Data available from 1/1/2013 forward)
Insulet (NASDAQ PODD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Insulet (PODD) Rating Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - April 26 at 7:48 AM |
| Insulet (PODD) Scheduled to Post Earnings on Thursday
www.americanbankingnews.com - April 26 at 1:56 AM |
 | Global Insulin delivery system Market Competitive landscape: Insulet Corporation, Animas Corporation
www.marketwatch.com - April 24 at 9:03 AM |
| Brokerages Anticipate Insulet Co. (PODD) Will Announce Quarterly Sales of $121.60 Million
www.americanbankingnews.com - April 23 at 5:32 AM |
| Zacks: Analysts Expect Insulet Co. (PODD) Will Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 21 at 1:20 AM |
| Insulet (PODD) Earns Buy Rating from Analysts at Berenberg Bank
www.americanbankingnews.com - April 20 at 9:22 AM |
| Insulet (PODD) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 8:07 PM |
| Insulet (PODD) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 14 at 4:46 PM |
 | Edited Transcript of PODD presentation 7-Mar-17 4:35pm GMT
finance.yahoo.com - April 12 at 9:53 AM |
| Insulet (PODD) Given "Buy" Rating at Wedbush
www.americanbankingnews.com - April 7 at 6:04 PM |
 | BRIEF-Insulet Corp Says CEO's 2017 Total Compensation Was $8.2 Mln Vs $6 Mln In 2016
www.reuters.com - April 6 at 4:59 PM |
| Insulet Co. (PODD) Expected to Announce Quarterly Sales of $121.60 Million
www.americanbankingnews.com - April 6 at 4:43 AM |
| Insulet Co. (PODD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 4 at 9:34 PM |
| Analysts Anticipate Insulet Co. (PODD) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 4 at 3:06 AM |
| Insulet (PODD) Coverage Initiated at Guggenheim
www.americanbankingnews.com - April 3 at 5:16 PM |
| Insulet (PODD) Upgraded by ValuEngine to "Buy"
www.americanbankingnews.com - April 3 at 10:32 AM |
| Global Insulin delivery system Market Opportunities 2018: Insulet Corporation, Ypsomed Holding AG, Becton
www.marketwatch.com - April 3 at 9:20 AM |
| Zacks Investment Research Upgrades Insulet (PODD) to Hold
www.americanbankingnews.com - March 25 at 10:56 PM |
| BidaskClub Upgrades Insulet (PODD) to Strong-Buy
www.americanbankingnews.com - March 23 at 7:56 PM |
| Insider Selling: Insulet Co. (PODD) EVP Sells 3,500 Shares of Stock
www.americanbankingnews.com - March 20 at 7:50 PM |
| Insulet (PODD) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 18 at 11:18 AM |
| Insider Selling: Insulet Co. (PODD) COO Sells 7,090 Shares of Stock
www.americanbankingnews.com - March 16 at 7:35 PM |
| Insider Selling: Insulet Co. (PODD) EVP Sells 7,250 Shares of Stock
www.americanbankingnews.com - March 16 at 7:33 PM |
| John A. Fallon Sells 9,000 Shares of Insulet Co. (PODD) Stock
www.americanbankingnews.com - March 16 at 7:33 PM |
| Insulet Co. (PODD) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 10 at 9:40 PM |
| Insulet (PODD) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 10 at 4:58 PM |
| David A. Lemoine Sells 641 Shares of Insulet Co. (PODD) Stock
www.americanbankingnews.com - March 8 at 9:50 PM |
| Insulet Co. (PODD) COO Sells $101,312.39 in Stock
www.americanbankingnews.com - March 8 at 9:35 PM |
| Analyst: Insulet On Track For Profitability In 2018
finance.yahoo.com - March 6 at 5:04 PM |
| 240,327 Shares in Insulet Co. (PODD) Purchased by OppenheimerFunds Inc.
www.americanbankingnews.com - March 6 at 11:36 AM |
| Insulet Co. (PODD) Position Increased by Arrowstreet Capital Limited Partnership
www.americanbankingnews.com - March 6 at 4:38 AM |
| Insulet (PODD) Coverage Initiated at BMO Capital Markets
www.americanbankingnews.com - March 5 at 8:24 PM |
| Sectoral Asset Management Inc Invests $6.52 Million in Insulet Co. (PODD) Stock
www.americanbankingnews.com - March 5 at 4:07 PM |
| 54,207 Shares in Insulet Co. (PODD) Purchased by Lombard Odier Asset Management USA Corp
www.americanbankingnews.com - March 3 at 4:42 PM |
| Insulet Co. (PODD) Stake Lowered by Next Century Growth Investors LLC
www.americanbankingnews.com - March 3 at 3:53 PM |
| Zacks: Analysts Expect Insulet Co. (PODD) Will Post Quarterly Sales of $121.60 Million
www.americanbankingnews.com - March 2 at 1:50 AM |
| -$0.19 EPS Expected for Insulet Co. (PODD) This Quarter
www.americanbankingnews.com - February 28 at 11:11 PM |
| Teacher Retirement System of Texas Has $1.37 Million Holdings in Insulet Co. (PODD)
www.americanbankingnews.com - February 28 at 5:07 PM |
| Insulet Corporation to Present at Upcoming Investor Conferences
finance.yahoo.com - February 28 at 9:02 AM |
| Insulet Co. (PODD) Holdings Reduced by Champlain Investment Partners LLC
www.americanbankingnews.com - February 27 at 5:38 AM |
| Q3 2018 Earnings Estimate for Insulet Co. Issued By Northcoast Research (PODD)
www.americanbankingnews.com - February 26 at 4:48 AM |
| Oppenheimer Weighs in on Insulet Co.'s Q3 2018 Earnings (PODD)
www.americanbankingnews.com - February 26 at 4:38 AM |
| Q1 2018 EPS Estimates for Insulet Co. Lowered by Analyst (PODD)
www.americanbankingnews.com - February 26 at 2:06 AM |
| William Blair Brokers Reduce Earnings Estimates for Insulet Co. (PODD)
www.americanbankingnews.com - February 26 at 2:06 AM |
| Research Analysts Set Expectations for Insulet Co.'s Q1 2018 Earnings (PODD)
www.americanbankingnews.com - February 26 at 2:06 AM |
| Swiss National Bank Has $6.82 Million Position in Insulet Co. (PODD)
www.americanbankingnews.com - February 25 at 6:38 AM |
| Insulet's (PODD) "Buy" Rating Reiterated at Jefferies Group
www.americanbankingnews.com - February 24 at 3:48 PM |
| Insulet (PODD) PT Raised to $88.00 at Canaccord Genuity
www.americanbankingnews.com - February 23 at 9:44 PM |
 | 8 Stocks Getting Multiple Analyst Upgrades and Downgrades After Earnings and News
www.msn.com - February 23 at 5:14 PM |
| Equities Analysts Offer Predictions for Insulet Co.'s Q4 2019 Earnings (PODD)
www.americanbankingnews.com - February 23 at 4:34 PM |
Insulet (NASDAQ:PODD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Insulet (NASDAQ:PODD) Income Statement, Balance Sheet and Cash Flow Statement
Insulet (NASDAQ PODD) Stock Chart for Thursday, April, 26, 2018
Loading chart…
